Hepatitis B Virus Reactivation After Switch to Cabotegravir/Rilpivirine in Patient with Low Hepatitis B Surface Antibody

• Published in: Emerging infectious diseases Vol. 30; no. 8; pp. 1668 - 1671
• Main Authors: Adachi, Eisuke, Sedohara, Ayako, Arizono, Kotaro, Takahashi, Kazuaki, Otani, Amato, Kanno, Yoshiaki, Saito, Makoto, Koga, Michiko, Yotsuyanagi, Hiroshi
• Format: Journal Article
• Language: English
• Published: United States U.S. National Center for Infectious Diseases 01.08.2024; Centers for Disease Control and Prevention
• Subjects: Acquired immune deficiency syndrome; AIDS; Anti-HIV agents; Anti-HIV Agents - therapeutic use; Antibodies; Antigens; Antiretroviral agents; Antiretroviral drugs; antiretroviral therapy; Antiviral agents; B cells; cabotegravir; Case studies; Complications and side effects; Diketopiperazines; Disease control; Dispatch; Drug therapy; Drugs; Enzymes; HBV; Hepatitis; Hepatitis B; Hepatitis B - drug therapy; Hepatitis B - virology; Hepatitis B Antibodies - blood; Hepatitis B Antibodies - immunology; Hepatitis B Surface Antigens - blood; Hepatitis B Surface Antigens - immunology; Hepatitis B virus; Hepatitis B virus - genetics; Hepatitis B virus - immunology; Hepatitis B Virus Reactivation after Switch to Cabotegravir/Rilpivirine in Patient with Low Hepatitis B Surface Antibody; Highly active antiretroviral therapy; HIV; HIV Infections - drug therapy; HIV Infections - virology; HIV patients; Humans; Infections; Infectious diseases; Liver; Male; Middle Aged; Mutation; Patients; Prevention; Pyridones - therapeutic use; Pyrimidines - therapeutic use; Rilpivirine; Risk factors; Vaccination; Vaccines; Viral antibodies; Virus Activation; Japan; viruses; HIV; hepatitis B; HBV reactivation; Japan; antiretroviral therapy; hepatitis B virus; vaccine-escape mutation; cabotegravir; HBV; rilpivirine
• ISSN: 1080-6040; 1080-6059; 1080-6059
• DOI: 10.3201/eid3008.240019

A patient in Japan with HIV began antiretroviral therapy because of acute hepatitis B virus (HBV) 15 years ago, with low hepatitis B surface antibody, and experienced breakthrough HBV reactivation 4 months after switching from bictegravir/emtricitabine/tenofovir alafenamide to cabotegravir/rilpivirine. An immune escape mutation, E164V, was identified in the isolated HBV DNA.